Let's get going. Good morning, guys. Jon Block with Stifel. Welcome to day two of the 2023 Stifel Healthcare Conference. We're going to kick things off this morning with Sientra, and with us, we have Ron Menezes, sorry, Chief Executive Officer. That's fine. That was better than last time, I think. Yeah. Andy Schmidt, Chief Financial Officer, and Oliver Bennett, Chief Legal, Compliance, and Corporate Development Officer. We're going to get into some Q&A. We were talking before, I think in aesthetics, a lot is going on. But Ron, you wanted to go over some slides first. Yeah. We'll have you kick that off, and then we'll jump into the fireside. Thanks, Jon. And, I just—this is the vision for the company, but, three key words I want you to think about is, one, safety, two is innovation, and three is best outcomes. That's what Sientra is all about. Let me drive in a couple things here. We are a comprehensive platform. One of the things that I did back in early 2021 is, how do we change this company into being an aesthetic and dermatology company to full plastic surgery company, and create a platform focused not just on aesthetic, but also reconstruction? And that's been the focus the last two or three years, diversify the company within plastic surgery, so you're not fully dedicated just to aesthetic and dependent on the up and down of aesthetic business, which, by the way, 2021 was excellent. You look at, to talk a little about our vision. So you have a company that has a CAGR rate of 25% the last three years, okay? So you continue growth, but one of the things we've been focused a lot is, how do we grow within this group, competing against two major competitors: AbbVie, Allergan, and Johnson & Johnson Mentor. We doubled our market share the last three years, so we're continuing to grow. But the other part that we've focused as well is profitability. We started to, the last 12-15 months, lowering our free cash flow dramatically to the point in the second quarter, it was less than $1 million in the second quarter, with the goal of being a profitable company next year. So we're continuing to do a lot of things to grow the top line, but really be an efficient company in order to drive profitability within the next 12-18 months. The team is an outstanding team. It's a really nice mix of team members from aesthetics, but also from medical device. You see from our head of sales, medical device experience, reconstruction experience. Our head of marketing has a broad experience, both aesthetics and medical device, and the two over here have incredible experience managing a small-cap, you know, companies as well as mid-size cap companies. And you look, what have we been doing the last 3 years? Bringing a new team was my goal in 2021, and also we make sure we are very focused. And then, we start adding new products, creating that platform, focus on innovation, accelerating a top line with a very robust, disciplined way to control cost. Now, how do we go from here? It is leveraging this platform, the commercial platform, leveraging the new products we have on board, and really focus on reconstruction. In 2021, 60% of our revenues came from the cosmetic aesthetic side, this year, 60% is going to come from the reconstruction side. So it's working. We're being more diversified. We have added new products, we acquire new technology, and it really prepares us as well for the future of this company. And everything already said here, so I'll go to you. Okay, perfect. Let's get into it, because- Oh, they put the whole slide deck, so I don't need this whole slide deck. Yeah, that's great. Yeah. We caught up earlier, and I cover aesthetics, and it was a pretty tough third quarter for a lot of players. Maybe if you guys can kick us off and just talk about... Let's stick to augmentation for now. Yeah. You know, what did you sort of see, call it, in the summer months, how that progressed into the fall? And then, is there any sort of an update that you can provide, even in the first, call it, month and a half of 4Q? Because I'll go to some of the other players that I do cover. You know, the consumer was weak in the third quarter, but there was a lot of chatter, I call it the exit, that the exit rate took another step down- Yeah ... in the month of September. So, you know, maybe just walk us through that past 3 or 4 months, up until today, if you can, on what you're seeing specific to August. Yeah, you know, as I just stated, 2021 exploded. We grew our top line close to 50%, and 60% driven by the augmentation side. But the aesthetic side is very typical. It goes up and down, depends on the consumer demand and the consumer flavor, and we saw that in 2021. 2022, it came back down to normal pre-COVID days, and we saw this year a unique summer, where a lot of consumer, and specifically in the augmentation side, delaying or not having breast augmentation, not because they're not interested, it's because they're pushing forward to the third, fourth quarter. So from a seasonality standpoint, third quarter is a traditional slow quarter for augmentation. Why? Because people are traveling, because people are in the beaches, people are in swimming pools, et cetera, but it was dramatically lower this quarter. We have seen some promising, numbers already for fourth quarter from, sequentially, it has a growth, already on that side. But it was a really unique, time this quarter, and I think everyone knows, as you, all of you have done your research, as part of it, 'cause the consumer's traveling. And, surgeons, I had a lot of surgeons that took two, three weeks off in August to leverage, the time they thought was going to be slow, which was very slow. Okay. And then, just to push on the other side of the business, you mentioned the transformation, right? 60% used to be Aug, now it's 60% Recon. But if we look at the third quarter results, can you talk to us a little bit what was going on in Recon? Because it, you know, most of what was light was specific to Aug. Yeah. But it seemed like Recon might have been... It's always hard to tease out the exact numbers, but that might have been a little bit light as well. And of course, Recon is what? Less discretionary- Correct ... should be more resilient. So anything to call out on the dynamics specific to Recon? Yeah, and it was, there was also lower surgical cases, unfortunately, and I actually just flew through a slide that showed that one out of eight women will unfortunately have to deal with breast cancer. So it didn't go away, and 50% of those patients go through reconstruction. It was more of a delayed. They pushed into the fall, late fall, their reconstruction, and I have to, you know, guess, due to travel, due to surgeons planning, and everything being scheduled. Three weeks ago, we were at the American Society of Plastic Surgeons Annual meeting in Austin. It's a big reconstruction meeting. 3,000 surgeons attend this meeting, and they all told us in multiple meetings that their cases are pretty booked up from October on for reconstruction into the first quarter next year. So this is kind of a typical drop because of different goals and different things that consumers doing that summer. Okay. And then, Andy, I'll pull you in and, you know, try to walk it over to the numbers. So you pulled the guide, right? But when we think about 4Q, that is usually up sequentially. Ron just talked a little bit about, you know, improving trends, recons, recon shouldn't have a ton of variability, and you have these new products that we'll get into in a moment. So, you know, I know, again, you don't have guidance out there, but when we think about those dynamics, should we assume some growth, 3Q to 4Q, on first the core business, you know, call it aug recon, and then on top of that, layering in some contribution from the new products? Sure. So you know, we certainly agree, Q4 is our best quarter. Every quarter for us, the third month of the quarter is always the tell. So you asked about October. You know, we see October, year-over-year, looking as it should, but it's gonna be the lowest month of a quarter. So December is really our go quarter. So right now, we're like everyone else in the industry, keeping our eye on it, seeing what we're gonna see coming. In terms of contribution, as Ron said, we expect recon to come back on schedule. Aug is very hard to put a thumb in the air on, just because of the different market dynamics. We have two great product launches. We launched Viality, though, in our Q2, more of a controlled launch, and then we launched SimpliDerm really in September, October timeline, so brand-new launch. So they will contribute in Q4, but since it's so new and we have to go through the hospital contracting cycle, which has varying timelines, it's very difficult to pinpoint exactly what that contribution will be in Q4. There'll be great contribution in 2024, but again, our Q4 is a little bit difficult to measure up, so we're just staying conservative and saying we're gonna let it play out and not try to predict it. Okay, that was helpful. Ron, I'll go back to you, 'cause, you know, in the slides, you went through one of the big things that you've also done is sort of worked on this product portfolio. You've got your sales force. You want to leverage the sales force and get, you know, more products to the end market and sort of strengthen the bundle. So let's discuss the pipeline. You got a handful of new complementary products being rolled out, right? I mean, Andy, you just touched on some of them, but Viality for fat grafting, SimpliDerm for ADM, and AlloX2 Pro finally through the FDA, the company's next gen tissue expander. From an investor standpoint, you hear about that from a relatively small company, and you sort of say: What should I be most focused on in the near term, and why? Yeah. So maybe just of those three that I just called out, you know, where should we really be sort of tuned in, and what could have the biggest impact as we go into 2024? All products, because it becomes a portfolio sell now. When you're dealing on the reconstruction side with a hospital, they like to deal with one vendor. Think about the hospital. That institution is dealing with multiple disease states, multiple vendors across all... So in this case, reconstruction, we are one of the only two companies that has all products available for the hospital. So it makes it easy for the hospital to deal just with us. Now, we know who the other company has, but we're the only company, like the other company, has great breast implants, you know, the fifth generation, as well as a unique tissue expander. We have a tissue dual port and single port. We're the only company that has a dual port tissue expander and a single port tissue expander. Why dual port is critical for that surgeon? Because it reduces infections. There are different advantages for that surgeon, for that patient to have a dual port, a tissue expander. We give options to the hospital. Then you come across to Viality fat grafting. We have a unique product that will go in a little more detail, and then we have SimpliDerm, the ADM as well, and then finally, we have other topical products. But bottom line, having that portfolio of products makes bundling easier, it makes contracting easier for the hospitals. We already have seen in some institutions, contracting with us the last 30 days, which will really sets us well for next year, and then next 2025 as well, as we start displacing the market leader. And now, other second for us is Viality fat grafting. Why is it everyone should be exciting? Because fat grafting is becoming a critical thing, not just for reconstruction, but for augmentation as well. 60%-80% of patients that go through reconstruction use fat. So think about that patient. She's gone through a mastectomy, so she has tissue, and she has chest muscle. So when you go through the process of putting tissue expander, you go the process of put a implant, they will put fat grafting around the implant to give more of the natural look. The challenge of the current products, products in the marketplace is they have a retention rate of 40%–50%. So you think about that surgeon, start to think, okay, half of that fat may be here a year from now, two years from now. So it's not predictable, so that surgeon's gonna have to do double. Sometimes 60% is there, sometimes 30%. The beautiful thing about Viality, we have 12-month data, clinical data, which the only product that's clinical data, that show it's over 80% fat retention at three, six months, and 12 months... and that data was presented just three weeks ago at ASPS. So now that surgeon has predictability, the surgeon understands what that will be there, and we are seeing an acceleration of more and more hospitals adopting Viality, and the reorder rate is at par or even higher the reorder rate with implants and tissue expanders. Just for an example, we had a seminar for Viality. We expected 40–50 surgeons to attend the seminar three weeks ago in Austin. We had 120 surgeons with standing room only for Viality data. So we're excited about Viality. SimpliDerm, it's an exciting addition. The market leader, AlloDerm, did over $400 million in sales the last time they shared the data back in 2019. Over $400 million. So this is now a $500 million plus TAM for us. This market leader has 80%, share. So if you think about it, if we start introducing more and more of this product, and you're looking at a total patient cost, would be... and a revenue for the company, about $20,000. If you add the implants, the tissue expander, Viality, and SimpliDerm, you're looking close to $20,000 per patient. Now, compare that to a cosmetic patient, $1,200, two implants. So that's one of another reason we focus on that. But we're focusing now on reconstruction, not just for the revenue, but also for innovation and safety. We're very proud of both Viality and SimpliDerm. You mentioned the importance of the bundle with the hospital, and they want to deal with one vendor. Do you have everything you need? So, you know, now that we think about fat grafting and ADM and the next gen tissue expander, which is differentiated, is there anything else that you need to bring into the bundle, or does this enable you to go to the hospital and sort of be the one-stop shop? This is at par with this main competitor. We'd like to have an edge over the main competitor, but we are in really good shape right now for negotiations with the VAC committees at different hospitals. Okay. And you know, one of the things that came up on the recent call was some of the contracting and the RFPs were taking a little bit longer than maybe you had initially anticipated. That might be, and I think you alluded to this earlier, a little bit of a headwind for Q4. Mm-hmm. But Ron, you just said you're starting to see them come through and win. Yeah. Like, is this still a bottleneck into 2024, or do you think, you know, some of those processes are largely behind you at that point, and 2024 will be more representative of your true win rate and share capture? Yeah. To go through the RFP and the VAC committee takes about 6–12 months. We now have the data Viality that we're going to present to those VAC committees. The 80%- The 80% data. It's the data, 12-month data, will be published beginning of next year. So we are starting to use that data to meet with the VAC committees, to submit the RFPs, and things are moving a little faster, much faster than they were just four or five months ago. And remember, it was a controlled launch. It was not a full launch. We started small institution, and then we went to some academic institutions. We were trying to learn how to go through the process. Now that we have the data, now that we have everyone trained, and then we have SimpliDerm, which just as well as the control launch in the last two months. So you'll be able to go to that VAC committees with the full portfolio of products and start presenting RFPs. Now, sometimes, the timing is not perfect for when they open up for RFPs for some of the VAC committees or from the hospitals. So with that, sometimes you have to be in the right timing to get access. Okay. And then, you know, obviously, what I always like to try to do is walk it back to the P&L- Yeah ... and what it does, it does or doesn't mean. So, you know, Andy, I'll throw some numbers by you. The base business is gonna do around $85 million, give or take, this year. Do we think about, you know, growth in that base for 2024? And when we talk about these products, is this an additional $6 million–$8 million contribution? How do I get $6 million–$8 million? That's sort of the, you know, the upper band of that 5%-10% that you've talked about in terms of the overall contribution. So is this grow the $85 million on the core, and then on top of that, this can be $6 million–$8 million incrementally? Sure, so I'll echo what Ron talked to in terms of a concept of a controlled launch. If you, if you consider the Sientra embedded base, okay, we got hundreds of hospitals, that launch will continue into 2024. So arguably, as we go through 2024, as we exit 2024, we'll have a goal of having all of our existing hospitals on contract, let's say. But that's gonna be incremental as we go. Now, when we look in terms of the possibilities for the product, what we've talked to before is, if you consider our, you know, our best-of-class tissue expander, that's, you know, an eight-figure business. So that's up to 20% of our revenue, just in tissue expander. If you look at the attach rates that Ron's talking to in terms of use of an ADM in a procedure, use of fat grafting in a procedure, it's consistent with the usage of a tissue expander. So the revenue can be at least, again, in the eight figures, if you have that same attach rate for a customer. And as, as we've talked to as a company before, hospitals like to buy from one vendor. So as we go in with the portfolio, the goal is to have all the products on contract, not just a few. So that's a plus for us. Okay. And then, you know, to stick with you, Andy, for a moment there, the margins of these products, because clearly, the push here, we'll get into the P&L in a little bit, or the balance sheet, but you want to turn the corner on free cash flow? Right. Right? So maybe talk about the margins, whether you want to talk about gross margin, or you've got the infrastructure with the reps there. Right. Just how this flows to the P&L and the contribution from a cash flow perspective. Sure. Again, kind of, again, echoing Ron, 2021 was the start of this migration more towards reconstruction business. The team here has been working not just in terms of the commercial side, but also the back end, in terms of how we build the business to support that. ... And the best part about what we're doing now is in 2023, we've taken out over 20% of expense from the model, so we're running at 2021 run rate expense. But again, higher, higher, revenue and higher revenue opportunity at that lower expense base. So what we're doing is we're creating the leverage in the model. So we go into the hospital with this bundle. It's the same salesperson selling the whole bundle versus selling one product. So now we're leveraging our number one expense, our sales and marketing spend. So we're creating the leverage model that we'll start realizing here in 2024. So that's that one building block from that perception- Okay - perspective. Okay. I'm going to pivot, Ron, and I'm just going to go to, you know, call it current and future market share. Yep. Let's break this down. Where do you currently sit? You know, when we think about augmentation and recon, and you've got these two really well-entrenched players out there, just help us with, you know, where you currently stand on the aug side and the recon, and then we'll get into where you think that can go. I'll start with recon side because we use the data we get from, like, IQVIA. We're about 20% overall for both tissue expanders in implants. Okay. Now, we're much higher on the tissue expanders, but overall average is 20%. And like I said, just three years ago, was in the 10%, so we doubled that share, and we see acceleration in the reconstruction. On the augmentation side is a unique... We used to get data from a vendor that got data from 400+ surgeons, and that they stopped providing that data. So the latest data we have, which is Q1, it was around 13%-14% share that time, which is again, double share versus where we were three years ago. So we have not had able to get access the last two quarters on for augmentation. I don't know if, Ollie, if you have anything else to add on that? No, I think that. Yeah ... that's a good summary of it. So, the pushback that I'll get from investors is, you know, you're 20% on recon- Yep ... you're, you know, almost mid-teens on aug, but there's those two players- Yep ... called Allergan and J&J, and you know, just in terms of their might. So where can this go? You know, for you guys, is it you need a better market, and you still think you can get some incremental share gains? And if so, like, where does it, do you really start to run into resistance when you think about, especially on the aug side, the bundling from an Allergan of the implant and the, you know, and the toxins, etcetera? Yeah. The augmentation side, the cosmetic side, it is more competitive. It is more relationship-based discussions with current and new. Viality has given us an ability to open several doors on the augmentation side because of the data and because the multiple users... Remember, Viality fat grafting is not just for the breast. There's multiple use, of the approved indication by the FDA, is broad use wherever there's fat need for fat grafting. So you're seeing the surgeons they use for BBL, Brazilian butt lift, or using as a facial. We have a study going on right now for using Viality in the face as a replacement for synthetic fillers. More and more surgeons are using fat instead of synthetic fillers. So we have all that's moving on. So that's really helping us. You know, even though we don't have a toxin or a filler, we have a natural filler, which is obviously Viality and fat. So we have the ability to open new doors, but it is more competitive. On the reconstruction side, we don't see a ceiling at all for share. We don't see where we stop because- Mm ...the ability to have those multiple products, a portfolio selling, and one of the great things, having our new head of sales, he has that experience of portfolio selling. So we're going to be really setting up new compensation for the reps, new broad things for the organization, for customers as well. The advantage of coming in and to not just talk about one product, but talk about the whole Sientra number of products that we have. So to your point on recon, like, look, hey, you know, we went from 10%-20% share without having the increased- Exactly - bundle for the most part. Exactly. Now, we've got our increased bundle. No ceiling there. No ceiling. On August 13-15, it's a little bit of a different dynamic. You know, we can still move higher- Yes ...notably, but it's going to be a little bit- Slower pace - more capped. It's slower pace. Okay. It's really leveraging the new products. But I do see, and then I said that about 1.5 years ago, is we have the ability as a company to be the leader in reconstruction because I knew the products would be coming in. Now, we have the products, we have the team. It's just a matter of accelerating the next 2–3 years. Okay, and you mentioned, just to go, you know, off script for a moment, Viality phase trial, when did you kick that off? Pardon me. What sort of duration, you know, will that trial run for? Like, when can we expect results, you know, to potentially open up yet another market opportunity for you guys? We'll let Oliver answer that. Yes. He was very involved in the acquisition. It's a- Yeah ... it's an independent trial. It's being run up at Massachusetts General Hospital right now, and there's 10 patients, and they're studying it up to 12 months, and they're looking at it in transgender patients. There was preliminary data presented at ASPS on that study, again, showing over 80% retention in the fat at the 12-month time period. It was really impressive results. Okay. And I'm sorry, you said 12 months? Twelve months. Okay, good. You know, just to push again on market share a little bit, we talked about the two entrenched players and you guys, and there might be another player- Mm-hmm ... you know, in the coming quarters, years, I guess, to be determined. Ron, when you look out, you know, is there any time expectations that you have, if and when that player might get there? Maybe you want to break that down between augmentation and recon. And then is it sort of a silly concern for you guys, where, you know, even on augmentation, you don't have 87% of the market, maybe you have 13. Yeah. You know, so if that player were to gain share, do you feel it's most likely to come from the two entrenched players, and that Sientra is a little bit more insulated there? ... Yeah, I'll take that. I think, you know, I think you hit on the first bit. There's uncertainty about, you know, when they'll come to the market. You know, we obviously have no visibility into how their study is going and then interactions with the FDA. Although we do know, you know, one of their clinical sites got FDA Form 483 for failing to properly report adverse events. Now, that presumably won't help their interactions with the FDA, but we have no idea what's going on there. Also, from what we've seen, they had a tissue expander cleared by the FDA recently, that's- Yep ... that's labeled textured, and so we would expect that their implants will be labeled textured. Now, that's a very small percentage of the U.S. market. It's about 5% of the U.S. market that if they get that texture labeling, that they would be competing for. That being said, right, you know, we think there's room for another competitor in the marketplace. We do see, you know, having two companies that are really focused on breast aesthetics can help maybe grow the market, and that can be beneficial to everybody. But to your point, you know, there are two companies that have 87% share of the market for augmentation. We would expect that, you know, when they come to the market, they'd be going after the lion's share, and not just focusing on Sientra. That wouldn't seem to make a lot of sense. Mm-hmm. And so, that their opportunity is with the big, the big companies that have the majority of the share. Yep. Okay. Okay, so you guys can continue to march higher, notably in recon and even in aug, even if, like, that fourth player comes to market? Right. You'll have two, two companies really focused on breast aesthetics. Obviously, and, you know, that can help grow the market and both taking share from the, the market incumbents. Okay. Andy, I'm gonna pivot to you. We've got five or so minutes left. The company ended the quarter with, I think, roughly $15 million in cash on the balance sheet. The goal was to get to free cash flow positive by the end of 2023, you know, but then, you know, the guidance came down, you pulled the guide. So maybe just talk about new goals or timing of turning the quarter on, on free cash flow. Sure. We feel as a group, we are firmly committed that we're at an inflection point. This is not an aspirational goal. Our Q2, which is, you know, not necessarily the best quarter of a year, we only burned $700,000, and what we've done over since 2021 is we've hit this at different angles. One is profitability. Obviously, we've taken over 20% cost out of the model while growing and introducing new products, so that gets you to kind of a good line of sight in terms of how we get cash flow positive from an EBIT perspective. The other part that we've been very successful on is really efficient use of our working capital. So we've used that as a lever over the last year and a half, especially the last five quarters, to help get us free cash flow positive. We still have a lot of room to do there, and just as a case in point, in our last quarter, reported quarter here, our Q3, you know, $19.5 million in revenue, which is unusually low for us. Again, seasonally low. We had a loss, cash loss of about $6 million, $6.3 million, but our cash burn was $3.6. That's utilizing the working capital again to our best advantage. As we go forward, we have well over $10 million of working capital leverage that we can use to work along with our drive to cash flow positive EBIT, so that we have two different levers to actually get us to that place. So we feel very confident that this is a quarter-to-quarter question; it's not aspirational-led. Perhaps by the end of the year, we can get cash flow positive. We had our eyes set on this quarter, but given all the market dynamics that you're well aware of in your coverage universe, you know, we're just being careful about what the market's gonna bring us this quarter. But in terms of the infrastructure, it's already been put in place. That work's been done. There's no more work to do on that infrastructure to get it right. In terms of working capital, it's been five consecutive quarters of performance demonstrating how we can leverage that, and we'll continue to leverage that. On the working capital side, where does that predominantly reside? Is that just the inventories and the ARs- Yep ... that we should focus on? Yep, exactly. Okay. And if you look at the last nine months, we have reduced operating expense by over 20%. We unfortunately had a bad third quarter, but our revenues are flattish, but our operating expense is down over 20%. Okay. And you know, you're doing everything you can with the working capital. You mentioned the $20 million quarter in 3Q. Just to go back to the free cash flow, where should we be focused from a top-line perspective? Mm. Is that, like, a $25 million-$30 million dollar- Yes ... per quarter number that you need to, to turn the corner there? Yes, that's the correct range and, you know, maybe more towards the $28 million–$30 million. But keep in mind, last year, without the new products, in fourth quarter, we did $25 million in revenue. So the jump from 25 to getting closer to 30, that basically, without market growth, can be picked up by new products. So we feel, again, we have everything in our arsenal here to actually get us there, regardless of what the market brings us. Okay. And just maybe to close with a couple of miscellaneous. Ron, back to you. AlloX2 Pro, you were very excited about that product. You highlighted it at one of your, you know, investor days. It's never easy with the agency, but you finally got it across the goal line. So, you know, congrats on that, but how about the timing, the launch? How do we think about that in 2024? I'll sort of start with that first question, then I'll go back to ASPS or- Yeah ... over to ASPS. I'll start and then I'll address it, but it... The exciting thing about this product is there's nothing in the marketplace. It was the first product cleared that's MRI compatible. It's a dual port, like as I stated before, that there are several advantages of dual port, so the patient doesn't have to remove the tissue expander if she has to go through MRI, which is to be the first time. And so there's a lot of advantages that the market is very excited for. Now, from a launch setting- ... we are gonna manufacture it ourselves. We try to figure out what's the best way to have the right COGS for the product. We have the capability in the suburbs of Milwaukee. We make our implants there. We're gonna make AlloX2 Pro ourselves, and we'll make it, you know, within our team. It goes back to Andy said, leveraging our structure, not just our commercial team, but we're leveraging our manufacturing team as well, our technology, our skill set and knowledge, all in-house, will be done all in-house, and we expect to launch that in 2024, probably in the first six months of 2024. In the first half. Ollie, anything? Yeah, I think just to add on to Ron's point, you know, the what's exciting about the AlloX2 Pro is it really is showing our continued innovation in this space because it's got the MRI compatibility feature, but it's got some other advantages, too, that are unique in the marketplace. So we've got a study that came out that showed it has negligible interference in radiation therapy. Really important. That means that they can plan to be able to provide radiation treatment to the patient while they've got the expander in. And that's really, really important. It also, it's approved to be used with an 18-gauge needle, which means the fill and the drain, 'cause we have the drain, is faster. That's better for the patient, it's more comfortable, and it's better for the physicians and their practice assistants 'cause they can fill it four times faster. Okay. And the last one for me, and it sort of ties, it's small, but it ties to sort of the free cash flow argument there. Just in the international markets, and you have, like, a lot of shots on goal in the international markets, Japan, Canada, Saudi Arabia. Is there a way to frame the run rate of those businesses collectively? You know, can that step function higher? And I bring that up 'cause I know it's small, but they're distributors. I'm guessing the structure is probably free cash flow positive, right? You know, lower margin disty- Yeah ... but again, you save it on the OpEx. So where collectively do those revenues sit? How do we think about the growth going forward and sort of the march to free cash flow positive? Ollie? So look, those markets, they're all exciting for us. They're in early stages. Japan was a little bit earlier, but it was really impacted by COVID. Yep. So sort of really think of Japan as really starting to launch again. But those markets, they're in early stages of launch, they're showing good growth, and a lot of opportunity in them. And, you know, as we've been growing internationally, more people are coming to us asking to have Sientra products overseas. So there's more opportunity to continue to add to that footprint and, and to, you know, to your point, to get some more revenue growth out of them and, and positive cash flow performance. Okay. Guys, any last-minute questions from the audience? Team Sientra, thank you very much.